Credo Beauty’s Post

Introducing Bryce Telford one of our radiation business partners at Nelson Labs! Bryce, is a leader in microbiology, bioburden and radiation sterilization making him a valuable asset to Sotera Health Company. Dive into the Sotera Health Academy today for more insights from Bryce and our other sterilization experts! #Bioburden #RadiationValidation #LabTesting #ExperSpotlight #SafeGuardingGlobalHealth #SoteraHealthAcademy

Had a wonderful time (as always) at the Oregon Bioscience Incubator and OTRADI monthly meetup last night. It was an especially informative session thanks to the panel discussion on Bioethics and Healthcare Decisions. A very engaged and thoughtful discussion with doctors Ruchi Thanawala, Murtaza Batla and William Hersh, MD. A key observation for me was the challenge practitioners face today as patients (admirably) do research to be better informed. In today's information age, practitioners encounter three main types of information when interacting with patients: * Information - True facts * Misinformation - Well-intentioned, but incorrect information * Disinformation - False facts spread on purpose I imagine it is especially challenging here in the U.S. where we are one of just two countries which allow direct-to-consumer drug ads on t.v. and other media. Do the people who see those ads critically evaluate them, comparing the improvements over a placebo? Add to that the misinformation and disinformation on the web and I can see it straining the ability of the provider to do the best for their patient. While the interplay of information trio is not unique to healthcare, its direct impact on patient health significantly heightens the challenge.

The FDA’s Lab Developed Tests (LDTs) final rule is shaking things up throughout the lab industry and marks the beginning of an era of increased federal scrutiny. Tune in for regulatory updates and an exclusive look at genetic and routine test trends, market shifts, industry insights, and more from the industry’s only Avalon Lab Trend Report covered by experts Julie Barnes, JD, CEO of Maverick Health Policy, and Mark Monane, M.D., MBA, Chief Medical Officer and Principal at the Monane Group during our May webinar. Watch now: https://ow.ly/XaGc50RC7bJ #AvalonHCS #Webinar #RoutineTesting #GeneticTesting

Smart solutions for better health by ENABLE Adherence. This great comic creatively illustrates our mission. 🇪🇺 💡

Before Covid the regulators were ahead of industry with a vision for #decentralizedtrials including leaders from FDA driving the CTTI recommendations paper. During the pandemic, industry surged ahead with adoption driven by risk to trials around the world. Industry never got ahead of regulations but started to get close. Today’s economy has made it challenging for industry to maintain the pace of adoption, but the regulators and policymakers are once again taking the lead in maintaining progress in the field. https://lnkd.in/eXdwbeCK

How many steps does it take to pass a Bill? Enough to make an impact like this! I’d like to extend a heartfelt thank you to Rep. Marilyn Strickland (D-WA-10) for cosponsoring the MVP Act (HR 2666 / S 4204). Your support is instrumental in advancing this crucial legislation. Now, let’s work together to bring it to a vote and get it across the finish line! This Act has the potential to amend Title XIX of the Social Security Act, codifying value-based purchasing arrangements under Medicaid and reforming price reporting—transformative changes that will expand access to innovative therapies. Your leadership is helping make this possible. Special shout-out to Jay Greissing for spearheading this effort with brilliant ideas that are reshaping the rare disease space and biotechnology investment. Big thanks also to Dean Suhr and Teryn Suhr of the MLD Foundation for their dedication in driving this bill forward! Let’s keep the momentum going to ensure we get the vote needed to pass this in both the House and Senate. #MVPAct #RareDisease #InnovativeTherapies #Legislation #GeneTherapy #Biotechnology BioMarin Pharmaceutical Inc.

Reflecting on the insightful discussions from the 2024 Future of Marketing Conference & 28th MAX Awards, J. Walker Smith shed light on the profound impact of GLP-1 medications like Ozempic and Wegovy on businesses. From junk food companies feeling the pinch to airlines witnessing reduced fuel consumption, the ripple effects are undeniable. 💡 Rep. David Schweikert's poignant speech on the falling fertility rates in the U.S. underscores a critical concern. 🚼 As Rep. Schweikert emphasized, addressing this issue is crucial to prevent death rates from surpassing birth rates within the next 15 years. This brings into focus the broader social implications of weight loss medications like Ozempic and Wegovy. When an individual's weight changes, so do their dating prospects. 💑 It's an intriguing angle to consider how the increasing use of weight loss medications might influence birth rate declines in the long term. How do you envision weight loss medications reshaping the business landscape? And what's your perspective on the future trajectory of anti-obesity medication? Share your insights below! 💬 #Ozempic #BusinessImpact #Healthcare #Innovation

Lonza C-II® undenatured type II collagen is the most researched brand of its kind, backed by over two decades of evidence-based research. With 20+ studies, including 11 human clinical trials, the science speaks for itself. A daily dose of 40 mg has been shown to improve joint flexibility by 3 degrees – 15 times more effectively than a placebo!. This means reduced joint discomfort after activity and enhanced knee comfort, empowering consumers to hit their daily step goals with ease. Learn more about how cutting-edge science is creating real opportunities for brands to improve consumer health. Discover More: https://bit.ly/4cZ28k4 #UCII #JointHealth #Collagen #ClinicalResearch #WellnessInnovation

Great summary by Shawn M. Schmitt from my interview of Michelle Tarver, MD, PhD and Dr. Jeff Shuren last week. The recording is available on our website if you missed it, but check out Shawn's summary for a quick synopsis of Key Takeaways! https://lnkd.in/gg-N6SHX

To all our friends in the biopharma industry, we say: Happy Clinical Trials Day! 🎉 The world owes thanks to everyone who has dedicated themselves to developing life-changing new treatments. Currently, 495,056 various studies are being conducted across 222 countries by an estimated 5,000,000 staff. There are also millions of people who put their hands up every year to participate in these trials, a contribution not to be forgotten. Advancements discovered in clinical trials have led to some of the great successes of modern history. Specific diseases have been virtually eliminated and quality of life has been improved for millions of individuals. We are humbled to be part of such a vital industry. HealthRFID gives thanks to all those within biopharma and their ongoing contribution to the betterment of public health. References: https://lnkd.in/g_AC-vmd https://lnkd.in/gCu8zNMy